Janus Living Inc. Class A-1 Common Stock vs Personalis Inc. Common Stock — how do they compare? Janus Living Inc. Class A-1 Common Stock trades at $29.12 (market cap $6.76B), while Personalis Inc. Common Stock trades at $16.07 (market cap $1.69B). The key difference: Janus Living Inc. Class A-1 Common Stock is far larger — about 4× Personalis Inc. Common Stock's market cap, and Janus Living Inc. Class A-1 Common Stock pays a 1.98% dividend while Personalis Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Janus Living Inc. Class A-1 Common Stock for 0 Days and Personalis Inc. Common Stock for 0 Days on average.
| JAN | PSNL | |
|---|---|---|
Market Cap | $6.76B | $1.69B |
Volume | 1,332,082 | 3,817,236 |
Sector | Real Estate | Health |
52-Week High | $31.76 | $18.38 |
52-Week Low | $22.88 | $5.04 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $6.85B | $1.52B |
Dividend Yield | 1.98% | — |
Signals from Pluang's Aura AI — not financial advice
JAN trades at $28.85, up 0.42% today, with a neutral technical signal. The company, a senior housing REIT, reported a net loss of $61.10M in 2025, though revenue grew to $771.17M. Analyst sentiment is strongly positive with a 100% buy rating and a $32.91 consensus price target, representing a 14% upside. Recent developments include closing a $1.25 billion credit facility and declaring quarterly dividends.
The outlook is cautiously optimistic, driven by strong analyst support and strategic growth initiatives. Key opportunities include accretive acquisitions funded by recent capital raises. Risks include persistent negative profit margins, execution challenges in integrating new assets, and sensitivity to interest rate changes affecting REIT valuations.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Janus Living, Inc. is a real estate investment trust that owns and operates senior housing communities in US. Its portfolio comprises roughly 34 communities across 10 states, structured under RIDEA arrangements and externally managed by Healthpeak Investment Management.
Read more on JAN →Personalis Inc. is a cancer genomics company that provides tumor- and blood-based DNA and RNA sequencing tests, including its NeXT Personal liquid biopsy test for cancer monitoring.
Read more on PSNL →